What is Leede Financial’s Estimate for PMN FY2025 Earnings?

Promis Neurosciences (NASDAQ:PMN) – Investment analysts at Leede Financial issued their FY2025 earnings per share estimates for Promis Neurosciences in a report issued on Monday, July 21st. Leede Financial analyst D. Loe forecasts that the company will earn ($0.21) per share for the year. Leede Financial currently has a “Moderate Buy” rating on the stock. The consensus estimate for Promis Neurosciences’ current full-year earnings is ($0.24) per share. Leede Financial also issued estimates for Promis Neurosciences’ FY2026 earnings at ($0.22) EPS, FY2027 earnings at ($0.11) EPS and FY2028 earnings at $0.17 EPS.

Several other equities analysts have also issued reports on the company. Guggenheim reaffirmed a “buy” rating and set a $6.00 price target on shares of Promis Neurosciences in a research note on Tuesday, April 1st. Maxim Group assumed coverage on Promis Neurosciences in a report on Monday, May 12th. They set a “buy” rating and a $3.00 target price on the stock. Finally, HC Wainwright assumed coverage on Promis Neurosciences in a report on Monday, July 14th. They set a “buy” rating and a $4.00 target price on the stock.

Promis Neurosciences Stock Up 3.0%

Shares of PMN opened at $0.91 on Thursday. Promis Neurosciences has a 12-month low of $0.38 and a 12-month high of $2.05. The firm has a market capitalization of $29.62 million, a PE ratio of -18.12 and a beta of -0.10. The stock’s fifty day simple moving average is $0.52 and its 200-day simple moving average is $0.67.

Promis Neurosciences (NASDAQ:PMN) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.07).

Hedge Funds Weigh In On Promis Neurosciences

A hedge fund recently bought a new stake in Promis Neurosciences stock. Allostery Investments LP purchased a new position in shares of Promis Neurosciences (NASDAQ:PMN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 195,111 shares of the company’s stock, valued at approximately $185,000. Allostery Investments LP owned 0.60% of Promis Neurosciences at the end of the most recent reporting period. 50.13% of the stock is owned by institutional investors and hedge funds.

About Promis Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.